New drug combo aims to improve leukemia treatment before transplant

NCT ID NCT07672262

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the transplant. The goal is to see if the new combo helps keep patients cancer-free longer and with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax and azacitidine
What this could lead to: If successful, this could offer a more effective and safer consolidation therapy for intermediate-risk AML patients before stem cell transplant, potentially reducing relapse.
What could go wrong: This is a phase 2 trial with 226 participants, so results are still preliminary. The combination may cause side effects like low blood counts or infections, and it may not prove better than standard chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CONSOLIDATION THERAPY INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.